SBRT + Atezolizumab + Bevacizumab in Resectable HCC
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study is evaluating the safety and tolerability of neoadjuvant stereotactic body
radiation therapy (SBRT) with atezolizumab and bevacizumab for treating resectable
hepatocellular carcinoma.
This study involves the following study interventions:
- Atezolizumab
- Bevacizumab
- Stereotactic Beam Radiation Therapy (SBRT)
- Surgery